Your browser is no longer supported. Please, upgrade your browser.
Settings
AXON Axovant Sciences Ltd. daily Stock Chart
AXON [NASD]
Axovant Sciences Ltd.
Index- P/E- EPS (ttm)-2.09 Insider Own0.60% Shs Outstand98.36M Perf Week32.12%
Market Cap2.58B Forward P/E- EPS next Y-2.81 Insider Trans109.67% Shs Float31.88M Perf Month31.13%
Income-212.20M PEG- EPS next Q-0.58 Inst Own33.10% Short Float11.47% Perf Quarter10.08%
Sales- P/S- EPS this Y-29.50% Inst Trans30.18% Short Ratio5.80 Perf Half Y84.12%
Book/sh1.68 P/B15.60 EPS next Y-19.10% ROA- Target Price29.25 Perf Year54.03%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range11.01 - 26.49 Perf YTD110.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-1.09% Beta-
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin- 52W Low137.97% ATR1.42
Employees69 Current Ratio5.20 Sales Q/Q- Oper. Margin- RSI (14)71.99 Volatility9.01% 6.50%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume2.65 Prev Close24.27
ShortableYes LT Debt/Eq0.00 EarningsAug 21 Payout- Avg Volume630.31K Price26.20
Recom1.90 SMA2027.94% SMA5020.61% SMA20043.40% Volume1,667,766 Change7.95%
Sep-08-17Resumed Evercore ISI Outperform $30
Jul-11-17Initiated Jefferies Buy
Jun-14-17Reiterated Oppenheimer Outperform $26 → $30
Dec-20-16Initiated Laidlaw Sell $7.50
Dec-07-16Initiated Oppenheimer Outperform $20
Jun-07-16Initiated Leerink Partners Outperform $22
Jan-08-16Initiated H.C. Wainwright Buy $35
Oct-22-15Initiated Piper Jaffray Overweight
Sep-25-15Reiterated Chardan Capital Markets Sell $9.50 → $8
Jul-15-15Initiated JMP Securities Mkt Outperform $36
Jul-13-15Initiated Robert W. Baird Outperform $29
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Jul-06-15Initiated Jefferies Buy $31
Jun-18-15Initiated Chardan Capital Markets Sell $10
Sep-19-17 08:35AM  Axovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2% Zacks +6.08%
03:00AM  Axovant Sciences Shows Rising Price Performance With Jump To 93 RS Rating Investor's Business Daily
Sep-12-17 08:02AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit -7.74%
03:00AM  Axovant Sciences Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Sep-11-17 08:40AM  Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock? Zacks +5.47%
Sep-06-17 01:35PM  Why September Will Be A 'Make Or Break' Month For These Biotechs Investor's Business Daily
09:23AM  Today's Bell Ringer, September 6, 2017 CNBC Videos
07:00AM  Axovant to Present at Two Upcoming Investor Conferences PR Newswire
Aug-30-17 10:56AM  QVT Financials Investments, Performance, Letters Insider Monkey
07:40AM  Featured Company News - AVEO Pharma's FOTIVDA(R) Licensed in EU for the Treatment of Advanced Renal Cell Carcinoma ACCESSWIRE
Aug-22-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Aug-21-17 04:15PM  Axovant to Move Stock Exchange Listing to Nasdaq PR Newswire
Aug-18-17 08:50AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks
08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Aug-14-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Aug-10-17 02:00PM  Roivant's Billion-Dollar Haul Shouldn't Buy Off Skepticism Bloomberg
08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Aug-09-17 06:41PM  [$$] SoftBank Leads $1.1 Billion Investment in Roivant Sciences The Wall Street Journal
10:43AM  A 32-year-old biotech CEO just raised $1.1 billion from SoftBank to give old drugs new life Business Insider
09:45AM  Biotech Wunderkind Raises $1.1 Billion To Fund Pharma Startups Forbes
Aug-07-17 11:57PM  Axovant reports 1Q loss Associated Press
07:10AM  Axovant reports 1Q loss Associated Press
07:00AM  Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates PR Newswire
Jul-26-17 02:04PM  Will Axovant Catch Lightning in a Bottle With Its Alzheimer's Drug? Motley Fool
Jul-21-17 02:42PM  3 Been-There-Done-That Biotech CEOs Who Are Doing it Again Motley Fool
Jul-18-17 08:32AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
Jul-17-17 07:00AM  3 Small Biotech Stocks Being Run by Proven Winners Motley Fool
Jul-10-17 08:45AM  Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman PR Newswire
08:00AM  Axovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International Conference PR Newswire
Jun-29-17 08:15AM  Earnings Review and Free Research Report: Axovant Sciences Reported Lower than Expected Earnings Accesswire
Jun-28-17 08:21AM  Is This the Next Home-Run Biotech Stock? Motley Fool +7.10%
Jun-20-17 08:15AM  Featured Company News - Juno Therapeutics Shared Updated Data for TRANSCEND NHL 001 Clinical Trial at the IMCL Conference in Switzerland Accesswire +7.43%
Jun-19-17 08:43AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
07:00AM  FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies PR Newswire
Jun-14-17 04:42PM  Rigorous Trial Design, Nice Risk/Reward Keep Analyst Anxious For Avoxant's Phase 3 MINDSET Data Benzinga
Jun-13-17 07:15AM  Axovant reports 4Q loss Associated Press
07:00AM  Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates PR Newswire
Jun-06-17 07:30AM  Axovant Strengthens Executive Team with Key Management Appointments PR Newswire
07:30AM  Axovant Announces Changes to Board of Directors PR Newswire
May-31-17 04:30PM  Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
Apr-18-17 03:43PM  Axovant: A New CEO Doesn't Change Anything Motley Fool
Apr-17-17 04:15PM  Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares PR Newswire
Apr-13-17 12:21PM  Shark Bites: You Don't Want to Play the Gambler Today TheStreet.com +11.11%
Apr-12-17 08:37AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
08:20AM  Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2% Zacks
Apr-11-17 04:29PM  What's Got Axovant Sciences Jumping 10% Today? Motley Fool +9.22%
02:55PM  New Captain, Same Ship for Axovant Bloomberg
07:30AM  Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism Accesswire
07:02AM  3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich Motley Fool
07:00AM  Axovant Sciences Ltd. Announces Pricing of $125M Public Offering of Common Shares PR Newswire
06:00AM  The State of Play in Axovant Sciences Investopedia
12:20AM  [$$] The $400 Million Man The Wall Street Journal
Apr-10-17 04:30PM  Axovant CEO David Hung Promises To Invest $10 Million As Company Moves To Raise $100 Million Forbes +22.54%
04:15PM  Biotechs Split: Axovant Rides CEO Swap, But Celgene Partner Dives Investor's Business Daily
04:05PM  Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares PR Newswire
01:50PM  Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk TheStreet.com
01:46PM  Why Axovant Sciences Is Soaring 25% Today Motley Fool
12:12PM  [$$] Axovant shares jump after Medivation founder named chief Financial Times
11:40AM  [$$] The $400 Million Man The Wall Street Journal
11:39AM  Axovant stock surges 28% on new CEO MarketWatch
11:18AM  A company developing a drug to treat Alzheimer's disease just got a new CEO and the stock is jumping Business Insider
10:00AM  Medivation Founder Takes Helm at Axovant, Shares Spike TheStreet.com
08:15AM  Medivation Founder David Hung Becomes CEO Of Axovant Sciences Forbes
08:15AM  Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors PR Newswire
Mar-21-17 04:30PM  Axovant Sciences to Present at Upcoming Scientific Meetings PR Newswire
Mar-20-17 04:35PM  Axovant Sciences Announces Presentation Time Change at Oppenheimer Healthcare Conference PR Newswire
Mar-17-17 08:30AM  Is the Options Market Predicting a Spike in Axovant Sciences (AXON) Stock? Zacks
Feb-27-17 04:30PM  Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire +7.59%
Feb-24-17 05:42PM  3 Biotech Long Shots: Boom Or Bust? Motley Fool
05:42PM  3 Biotech Long Shots: Boom Or Bust? at Motley Fool
Feb-18-17 01:04PM  AXOVANT SCIENCES LTD. Financials
Feb-15-17 07:34PM  Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next? Motley Fool
07:34PM  Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next? at Motley Fool
11:15AM  [$$] Merck's drug failure deals further blow to Alzheimer's theory at Financial Times
Feb-14-17 05:54PM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
05:31PM  Axovant reports 3Q loss Associated Press
04:15PM  Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016 PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
Feb-13-17 09:19AM  Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More -6.47%
07:07AM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Other Events
07:00AM  Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients PR Newswire
Feb-08-17 11:35AM  Axovant Rival's Alzheimer Drug Fails Study at Investopedia
Feb-03-17 05:18PM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial +14.38%
07:00AM  Axovant Sciences Announces $55.0 Million Venture Debt Financing from Hercules Capital PR Newswire
Jan-25-17 04:30PM  Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
Jan-09-17 07:11AM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:00AM  Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference PR Newswire
Dec-28-16 08:55AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
Dec-20-16 09:06AM  Coverage initiated on Axovant Sciences by Laidlaw
Dec-09-16 04:15PM  Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer PR Newswire
Dec-08-16 03:29PM  Is Axovant Sciences Ltd (AXON) Worthy of Your Portfolio? at Insider Monkey
Dec-05-16 04:30PM  Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer's Disease at CTAD 2016 PR Newswire
Nov-28-16 02:12PM  Axovant Sciences Ltd. :AXON-US: Earnings Analysis: Q2, 2017 By the Numbers : November 28, 2016
Nov-25-16 07:00AM  Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
Nov-23-16 05:01PM  Eli Lilly's Alzheimer's Drug Is a Bust at Motley Fool
02:49PM  Five Lessons From Today's Pharma Failures at Forbes
11:41AM  Another failure in search for treatment to slow Alzheimer's
08:41AM  Trending Stocks: First Solar, Inc. (FSLR), Eli Lilly and Co (LLY), and More at Insider Monkey
Nov-08-16 04:24PM  Can Small-Cap Biotech Take On Gilead, Celgene, Biogen In Alzheimer's? -7.24%
Nov-07-16 06:40PM  Axovant reports 2Q loss +6.65%
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VERNON W ANTHONYDirectorApr 17Buy18.5453,937999,99253,937Apr 19 04:08 PM
FALBERG KATHRYN EDirectorApr 17Buy18.5453,937999,99253,937Apr 19 04:07 PM
Hung DavidPrincipal Executive OfficerApr 17Buy18.54539,37510,000,013539,375Apr 19 04:06 PM